Quarterly ResultAug 3, 2026, 07:22 AM
Ocular Therapeutix Q2 Net Loss $(78.76)M; Revenue $13.48M
AI Summary
Ocular Therapeutix reported a net loss of $(78.76) million for the second quarter of 2026, an increase from $(67.81) million in the same period last year, despite a slight rise in product revenue to $13.48 million. The company experienced a significant increase in research and development expenses, reaching $54.14 million, reflecting ongoing investments in its pipeline, including Phase 3 clinical trials for AXPAXLI. Cash and cash equivalents decreased to $598.64 million, with net cash used in operating activities for the first half of 2026 totaling $(133.27) million, though management believes current cash resources are sufficient for at least the next 12 months.
Key Highlights
- Net loss for Q2 2026 was $(78.76) million, compared to $(67.81) million in Q2 2025.
- Product revenue, net, for Q2 2026 was $13.48 million, a slight increase from $13.40 million in Q2 2025.
- Research and development expenses increased to $54.14 million in Q2 2026 from $51.08 million in Q2 2025.
- Cash and cash equivalents decreased to $598.64 million as of June 30, 2026, from $737.06 million at Dec 31, 2025.
- Net cash used in operating activities for H1 2026 was $(133.27) million, up from $(99.91) million in H1 2025.
- Accumulated deficit reached $(1,324.40) million as of June 30, 2026.
- Company expects existing cash to fund operations for at least 12 months.
- Ongoing Phase 3 clinical trials for AXPAXLI in wet AMD and NPDR continue.
Price Impact
More from OCUL